Ovarian Neoplasms
Conditions
Keywords
Ovarian Neoplasms, homologous recombination deficiency, prognosis, Cost-effectiveness analysis
Brief summary
Clinicopathological data were collected from ovarian cancer patients treated with PARP inhibitors, with follow-up imaging conducted before and after treatment. The efficacy was evaluated according to RECIST criteria, comparing the correlation between different HRD statuses and the efficacy of PARP inhibitors in ovarian cancer.
Interventions
GENETIChomologous recombination deficiency
Homologous Recombination Deficiency (HRD) refers to a disruption or deficiency in the homologous recombination repair (HRR) pathway, which is a crucial mechanism in cells for repairing DNA double-strand breaks (DSBs). This pathway is particularly important for maintaining genomic stability.
Sponsors
Fujian Provincial Hospital
Fujian Cancer Hospital
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients diagnosed with ovarian cancer (any histological type) and possessing complete pathological hematoxylin and eosin (HE) stained slides and paraffin-embedded tissue blocks. * Patients must be 18 years of age or older. * Patients should not have concurrent multiple primary cancers. * Patients must undergo an MRI or CT scan prior to starting treatment. * According to RECIST (Response Evaluation Criteria In Solid Tumors) criteria, patients must have at least one measurable lesion. * Participants must provide informed consent, voluntarily cooperate with clinical follow-up, and sign an informed consent form.
Exclusion criteria
* Patients who do not have accessible tumor tissue required for Homologous Recombination Deficiency (HRD) testing. * Patients whose clinical records are incomplete, making it impossible to effectively compare treatment efficacy. * Patients who are lost to follow-up and for whom subsequent treatment outcomes cannot be tracked.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy of PARP inhibitors in the treatment of ovarian cancer | 2026-5-1 | Progression-Free Survival (PFS) is used to evaluate the efficacy of PARP inhibitor treatment in ovarian cancer with different HRD (Homologous Recombination Deficiency) statuses. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| cost-effectiveness analysis of using PARP inhibitors to treat cervical cancer | 2026-5-1 | The main economic outcome is the ICER.Health benefits were expressed as life years (LYs), and quality-adjusted life-years (QALYs) gained. The ICER was calculated by dividing the incremental cost difference between the two strategies, by the incremental difference in health outcomes (LYs and QALYs). Probabilistic Sensitivity Analysis (PSA) was performed to assess the impact of uncertainty around the key parameters of the model on the ICER. A second-order Monte Carlo simulation with 1000 iterations was used to run replicated outcomes. The normal distributions used for costs, utility and reimbursement ratio were carried to the specific limits. |
| PARP inhibitors in the treatment of ovarian cancer | 2026-5-1 | Overall survival (OS) was used toevaluate the efficacy of PARP inhibitor treatment in ovarian cancer with different HRD (Homologous Recombination Deficiency) statuses. |
Contacts
Primary ContactJian FC Chen
Backup ContactYang Sun
Outcome results
None listed